Insider Selling: Illumina (NASDAQ:ILMN) Director Sells 119,501 Shares

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 119,501 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the completion of the sale, the director owned 770,350 shares in the company, valued at $168,244,440. This represents a 13.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Illumina Stock Down 1.6%

Illumina stock traded down $3.44 during trading on Friday, hitting $218.22. 1,728,019 shares of the company were exchanged, compared to its average volume of 1,904,505. The company has a market capitalization of $32.95 billion, a P/E ratio of 40.71, a PEG ratio of 3.02 and a beta of 1.46. The business’s 50 day moving average is $197.58 and its 200 day moving average is $158.61. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $231.81. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the previous year, the firm earned $1.19 EPS. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts predict that Illumina, Inc. will post 5.36 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Amundi grew its position in shares of Illumina by 2.6% in the second quarter. Amundi now owns 361,203 shares of the life sciences company’s stock valued at $63,510,000 after purchasing an additional 9,204 shares in the last quarter. HighTower Advisors LLC lifted its holdings in Illumina by 1.2% during the 2nd quarter. HighTower Advisors LLC now owns 40,134 shares of the life sciences company’s stock worth $7,057,000 after purchasing an additional 481 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Illumina in the 2nd quarter worth about $51,995,000. California State Teachers Retirement System grew its holdings in Illumina by 16,869.5% during the 2nd quarter. California State Teachers Retirement System now owns 40,144,099 shares of the life sciences company’s stock valued at $7,058,537,000 after buying an additional 39,907,533 shares in the last quarter. Finally, Guardian Wealth Advisors LLC NC purchased a new position in Illumina during the 2nd quarter valued at about $257,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. TD Cowen upped their target price on Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a report on Friday, July 31st. Leerink Partners boosted their price objective on Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. JPMorgan Chase & Co. boosted their price target on shares of Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Zacks Research cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Finally, Royal Bank Of Canada increased their price objective on Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $191.31.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Argus raised its price target for Illumina (ILMN) from $180 to $235 and upgraded the stock to “buy,” implying additional upside from recent levels. The bullish view reflects confidence in Illumina’s earnings outlook and continued demand for genomic sequencing.
• Neutral Sentiment: Broader biotechnology coverage was mixed. 10x Genomics’ strong rally, supported by consumables growth and improved guidance, highlights investor interest in life-sciences tools, although weak instrument demand and valuation concerns remain sector risks. 10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
• Neutral Sentiment: Articles about robotics and AI-focused ETFs may support long-term interest in technology and automation themes, but they do not represent a direct catalyst for Illumina’s business or stock. Are Robots the New Normal? Bet on these ETFs to Invest in the Future
• Negative Sentiment: Zacks Research downgraded ILMN from “strong buy” to “hold.” The change introduces caution after the stock’s substantial advance and suggests that current valuation and expectations may leave less room for execution missteps. Illumina Analyst Downgrade
• Negative Sentiment: PacBio’s reduced 2026 outlook, attributed to weaker instrument demand and slower clinical adoption, is a modest negative read-through for the sequencing market. Although PacBio is a competitor rather than an Illumina subsidiary, the update raises questions about the pace of demand across the industry. PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.